Veracyte, Inc. reported earnings results for the fourth quarter and full year ended December 31, 2025. For the fourth quarter, the company reported sales was USD 0.962 million compared to USD 3.46 million a year ago. Revenue was USD 140.64 million compared to USD 118.63 million a year ago. Net income was USD 41.15 million compared to USD 5.11 million a year ago. Basic earnings per share from continuing operations was USD 0.52 compared to USD 0.07 a year ago. Diluted earnings per share from continuing operations was USD 0.51 compared to USD 0.06 a year ago.
For the full year, sales was USD 9.66 million compared to USD 13.15 million a year ago. Sales was USD 9.66 million compared to USD 13.15 million a year ago. Sales was USD 9.66 million compared to USD 13.15 million a year ago. Sales was USD 9.66 million compared to USD 13.15 million a year ago. Revenue was USD 517.15 million compared to USD 445.76 million a year ago. Revenue was USD 517.15 million compared to USD 445.76 million a year ago. Revenue was USD 517.15 million compared to USD 445.76 million a year ago. Revenue was USD 517.15 million compared to USD 445.76 million a year ago. Net income was USD 66.35 million compared to USD 24.14 million a year ago. Net income was USD 66.35 million compared to USD 24.14 million a year ago. Net income was USD 66.35 million compared to USD 24.14 million a year ago. Net income was USD 66.35 million compared to USD 24.14 million a year ago. Basic earnings per share from continuing operations was USD 0.84 compared to USD 0.32 a year ago. Basic earnings per share from continuing operations was USD 0.84 compared to USD 0.32 a year ago. Basic earnings per share from continuing operations was USD 0.84 compared to USD 0.32 a year ago. Basic earnings per share from continuing operations was USD 0.84 compared to USD 0.32 a year ago. Diluted earnings per share from continuing operations was USD 0.82 compared to USD 0.31 a year ago. Diluted earnings per share from continuing operations was USD 0.82 compared to USD 0.31 a year ago. Diluted earnings per share from continuing operations was USD 0.82 compared to USD 0.31 a year ago. Diluted earnings per share from continuing operations was USD 0.82 compared to USD 0.31 a year ago.
Veracyte, Inc. is a global diagnostics company. The Company enables clinicians with insights they need to guide and assure patients. The Company offers tests for thyroid cancer (Afirma), prostate cancer (Decipher Prostate), breast cancer (Prosigna), interstitial lung diseases (Envisia), and bladder cancer (Decipher Bladder). Its Percepta Nasal Swab test is being run in its Clinical Laboratory Improvement Amendments (CLIA) lab in support of clinical studies and its tests for kidney cancer and lymphoma are in development, the latter as a companion diagnostic. Its products consist of the Prosigna breast cancer assay, the nCounter Analysis System, related diagnostic kits, and services. In the United States, it offers laboratory developed tests (LDTs), through its CLIA labs in South San Francisco and San Diego, California, supported by its cytopathology know-how in Austin, Texas. The Company also offers whole-genome MRD platform that enable it in early cancer diagnosis and risk assessment.
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
ESG MSCI
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
